drugset
drugset / Trial / NCT05355766

Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients

NCT05355766 ↗

Phase 2 Completed 16 enrolled Hangzhou Zede Pharma-Tech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The safety and efficacy of CN128 is studied in thalassaemia with sever liver iron overloaded patients.

Timeline

Start
2022-06-13
Primary completion
2024-09-23
Completion
2025-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CN128 Unknown 30 mg/kg Oral

Indications

disorder of iron metabolism and transport thalassemia